Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew A Gubens

Showing results (21-30 of 59) with videos related to

Pageof 6
Sort By:
Lung Cancer (Amsterdam, Netherlands)|March 20, 2019
Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and HMatthew A Gubens, Lecia V Sequist, James P Stevenson, et al.
JAMA Oncology|April 11, 2024
American Radium Society Appropriate Use Criteria for Unresectable Locally Advanced Non-Small Cell Lung CancerGeorge Rodrigues, Kristin A Higgins, Andreas Rimner, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 9, 2019
Incorporation of a Molecular Prognostic Classifier Improves Conventional Non-Small Cell Lung Cancer StagingJohannes R Kratz, Greg J Haro, Nancy R Cook, et al.
JAMA Network Open|September 30, 2020
Evaluation of a National Comprehensive Cancer Network Guidelines-Based Decision Support Tool in Patients With Non-Small Cell Lung Cancer: A Nonrandomized Clinical TrialSusan Y Wu, Ann A Lazar, Matthew A Gubens, et al.
JAMA Oncology|May 15, 2023
American Radium Society Appropriate Use Criteria for Radiation Therapy in the Multidisciplinary Management of Thymic CarcinomaStephen G Chun, Andreas Rimner, Arya Amini, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 4, 2019
Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLCFabrice Barlesi, Edward B Garon, Dong-Wan Kim, et al.
Medrxiv : the Preprint Server for Health Sciences|July 1, 2024
Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse eventsPooja Middha, Rohit Thummalapalli, Zoe Quandt, et al.
JTO Clinical and Research Reports|November 25, 2022
The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective StudyDavid J Benjamin, Shuai Chen, Joanna B Eldredge, et al.
Journal for Immunotherapy of Cancer|March 28, 2025
Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse eventsPooja Middha, Rohit Thummalapalli, Zoe Quandt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2021
Management of Stage III Non-Small-Cell Lung Cancer: ASCO GuidelineMegan E Daly, Navneet Singh, Nofisat Ismaila, et al.
Pageof 6

Showing results (21-30 of 59) with videos related to

Sort By:
Pageof 6
Lung Cancer (Amsterdam, Netherlands)|March 20, 2019
Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and HMatthew A Gubens, Lecia V Sequist, James P Stevenson, et al.
JAMA Oncology|April 11, 2024
American Radium Society Appropriate Use Criteria for Unresectable Locally Advanced Non-Small Cell Lung CancerGeorge Rodrigues, Kristin A Higgins, Andreas Rimner, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 9, 2019
Incorporation of a Molecular Prognostic Classifier Improves Conventional Non-Small Cell Lung Cancer StagingJohannes R Kratz, Greg J Haro, Nancy R Cook, et al.
JAMA Network Open|September 30, 2020
Evaluation of a National Comprehensive Cancer Network Guidelines-Based Decision Support Tool in Patients With Non-Small Cell Lung Cancer: A Nonrandomized Clinical TrialSusan Y Wu, Ann A Lazar, Matthew A Gubens, et al.
JAMA Oncology|May 15, 2023
American Radium Society Appropriate Use Criteria for Radiation Therapy in the Multidisciplinary Management of Thymic CarcinomaStephen G Chun, Andreas Rimner, Arya Amini, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 4, 2019
Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLCFabrice Barlesi, Edward B Garon, Dong-Wan Kim, et al.
Medrxiv : the Preprint Server for Health Sciences|July 1, 2024
Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse eventsPooja Middha, Rohit Thummalapalli, Zoe Quandt, et al.
JTO Clinical and Research Reports|November 25, 2022
The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective StudyDavid J Benjamin, Shuai Chen, Joanna B Eldredge, et al.
Journal for Immunotherapy of Cancer|March 28, 2025
Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse eventsPooja Middha, Rohit Thummalapalli, Zoe Quandt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2021
Management of Stage III Non-Small-Cell Lung Cancer: ASCO GuidelineMegan E Daly, Navneet Singh, Nofisat Ismaila, et al.
Pageof 6